ATE450512T1 - Enantioselektive herstellung von chinolin- derivaten - Google Patents

Enantioselektive herstellung von chinolin- derivaten

Info

Publication number
ATE450512T1
ATE450512T1 AT05770221T AT05770221T ATE450512T1 AT E450512 T1 ATE450512 T1 AT E450512T1 AT 05770221 T AT05770221 T AT 05770221T AT 05770221 T AT05770221 T AT 05770221T AT E450512 T1 ATE450512 T1 AT E450512T1
Authority
AT
Austria
Prior art keywords
quinoline derivatives
enantioselective production
enantioselective
production
quinoline
Prior art date
Application number
AT05770221T
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE450512(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE450512T1 publication Critical patent/ATE450512T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05770221T 2004-06-22 2005-06-21 Enantioselektive herstellung von chinolin- derivaten ATE450512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds
PCT/EP2005/006686 WO2005123684A2 (en) 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative

Publications (1)

Publication Number Publication Date
ATE450512T1 true ATE450512T1 (de) 2009-12-15

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770221T ATE450512T1 (de) 2004-06-22 2005-06-21 Enantioselektive herstellung von chinolin- derivaten

Country Status (32)

Country Link
US (2) US20090054653A1 (de)
EP (1) EP1791820B1 (de)
JP (1) JP5064214B2 (de)
KR (1) KR101179302B1 (de)
CN (1) CN1968927B (de)
AR (2) AR049553A1 (de)
AT (1) ATE450512T1 (de)
AU (1) AU2005254698B2 (de)
BR (1) BRPI0512298A (de)
CA (1) CA2566388C (de)
CY (1) CY1109884T1 (de)
DE (1) DE602005018076D1 (de)
DK (1) DK1791820T3 (de)
EC (1) ECSP067100A (de)
ES (1) ES2337273T3 (de)
GB (1) GB0413960D0 (de)
HR (1) HRP20100087T1 (de)
IL (1) IL179600A (de)
MA (1) MA28687B1 (de)
MX (1) MXPA06014695A (de)
MY (1) MY142051A (de)
NO (1) NO339079B1 (de)
NZ (1) NZ551276A (de)
PE (1) PE20060304A1 (de)
PL (1) PL1791820T3 (de)
PT (1) PT1791820E (de)
RU (1) RU2383534C2 (de)
SI (1) SI1791820T1 (de)
TN (1) TNSN06408A1 (de)
TW (1) TWI347317B (de)
WO (1) WO2005123684A2 (de)
ZA (1) ZA200609257B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713951B8 (pt) 2006-06-30 2021-05-25 Novartis Ag derivados de quinazolina, e composição farmacêutica
EP1914227A1 (de) * 2006-08-31 2008-04-23 Novartis AG Kristalline Polymorphe Form von Indan-2-ylamino-hydroxyethyl-quinolinon-maleat Derivat als beta-Adrenorezeptor-Agonist
WO2011056929A1 (en) 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
JP6058698B2 (ja) 2012-01-13 2017-01-11 ノバルティス アーゲー Ｉｐ受容体アゴニストの塩
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
EP3848354B1 (de) 2012-09-21 2022-07-27 Crystal Pharma, S.A.U. Verfahren zur herstellung von indacaterol und zwischenprodukte davon
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
ES2715682T3 (es) 2012-12-19 2019-06-05 Novartis Ag Inhibidores de la autotaxina
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
CA2898700C (en) 2013-03-14 2022-07-19 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2978745B1 (de) 2013-03-27 2017-03-15 Laboratorios Lesvi, S.L. Verfahren zur herstellung von (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-on
EP3022201A1 (de) 2013-07-18 2016-05-25 Novartis AG Autotaxinhemmer
MX368059B (es) 2013-07-18 2019-09-18 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica.
EP3092217B1 (de) 2014-01-09 2020-06-03 Davuluri, Ramamohan Rao Neuartiges verfahren zur herstellung von indacaterol oder dessen pharmazeutisch verträglichen salzen
EP3122331A1 (de) 2014-03-27 2017-02-01 Novartis AG Sprühgetrocknete feststoff-in-öl-in-wasser-dispersionen zur inhalation aktiver pharmazeutischer inhaltsstoffe
EP3134398A1 (de) 2014-04-24 2017-03-01 Novartis Ag Autotaxinhemmer
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
JP6621442B2 (ja) * 2016-05-17 2019-12-18 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 金属イオンバッテリー
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN114591236A (zh) * 2020-12-02 2022-06-07 四川海思科制药有限公司 一种茚达特罗的改进制备方法
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
TR199802385T2 (xx) * 1996-05-20 1999-04-21 Darwin Discovery Limited TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20100399A1 (es) * 2003-04-02 2010-06-01 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas

Also Published As

Publication number Publication date
AR049553A1 (es) 2006-08-16
DK1791820T3 (da) 2010-04-06
NO20070400L (no) 2007-03-21
NZ551276A (en) 2010-06-25
RU2383534C2 (ru) 2010-03-10
TNSN06408A1 (en) 2008-02-22
KR20070029752A (ko) 2007-03-14
EP1791820B1 (de) 2009-12-02
SI1791820T1 (sl) 2010-04-30
NO339079B1 (no) 2016-11-07
CY1109884T1 (el) 2014-09-10
AU2005254698B2 (en) 2008-09-25
ZA200609257B (en) 2008-07-30
AR082981A2 (es) 2013-01-23
US20090054653A1 (en) 2009-02-26
CN1968927A (zh) 2007-05-23
IL179600A0 (en) 2007-05-15
DE602005018076D1 (de) 2010-01-14
KR101179302B1 (ko) 2012-09-03
CA2566388A1 (en) 2005-12-29
IL179600A (en) 2011-11-30
MA28687B1 (fr) 2007-06-01
MY142051A (en) 2010-08-30
HK1105121A1 (en) 2008-02-01
HRP20100087T1 (hr) 2010-06-30
PL1791820T3 (pl) 2010-05-31
GB0413960D0 (en) 2004-07-28
PE20060304A1 (es) 2006-05-19
TW200615265A (en) 2006-05-16
CN1968927B (zh) 2010-07-21
US20120220775A1 (en) 2012-08-30
PT1791820E (pt) 2010-02-23
WO2005123684A2 (en) 2005-12-29
ECSP067100A (es) 2007-01-26
BRPI0512298A (pt) 2008-03-25
CA2566388C (en) 2013-04-16
TWI347317B (en) 2011-08-21
WO2005123684A3 (en) 2006-06-01
JP5064214B2 (ja) 2012-10-31
MXPA06014695A (es) 2007-02-12
JP2008503526A (ja) 2008-02-07
RU2007102228A (ru) 2008-07-27
ES2337273T3 (es) 2010-04-22
AU2005254698A1 (en) 2005-12-29
EP1791820A2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
ATE450512T1 (de) Enantioselektive herstellung von chinolin- derivaten
CY2022001I1 (el) Παραγωγα του uk-2a
DE602004000740D1 (de) Herstellung von Nuten
DE112007001307A5 (de) Mikrobiologische Herstellung von 3-Hydroxyisobuttersäure
IS8439A (is) Nýjar kínólín afleiður
CY2015015I1 (el) Παραγωγη τιακουμυκινης
DE602005011285D1 (de) Formmasse von polymer
ATE461285T1 (de) Herstellung von tnfr-fc
DE602005010568D1 (de) Enzymunterstützte Herstellung löslichen Kaffees
EP1969123A4 (de) Neue enzyme
DE502007000190D1 (de) Kontinuierliche Herstellung von Organosilanen
HRP20150163T1 (xx) Postupak za proizvodnju n-supstituiranih 2-cijanopirolidina
DE602004019472D1 (de) Herstellungsverfahren von Membran-Elektroden-Einheiten
EP1799875A4 (de) Herstellung von eisenlegierungen
DE602004023786D1 (de) Herstellung von hochreinem Alkylgallium
IS8416A (is) Aðferð við framleiðslu á CCR-2 mótlyfi
DE60323456D1 (de) Herstellung von Nanopartikeln
DE602004029836D1 (de) Herstellung von Turbinenelementen
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
DE502005000305D1 (de) Photobioreaktor
DE60326321D1 (de) Herstellungsverfahren von Farbstoffen
DE602004013599D1 (de) Herstellung von somatostatinpeptiden
FI20041430A7 (fi) Etanolin valmistus
DE602005011294D1 (de) Verbessertes verfahren zur herstellung von mirtazapin
NO20083028L (no) Ny fremgangsmåte for fremstilling av esomeprazol ikke-salt form

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1791820

Country of ref document: EP